Role of Allogeneic HCT as Postremission Therapy for Transplant-Eligible Adult Lymphoblastic Leukemia/Lymphoma After Frontline Hyper-CVAD

Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with cytarabine and methotrexate (hyper-CVAD) is a commonly used regimen in adults with acute lymphoblastic leukemia (ALL)/lymphoblastic lymphoma (LBL). We retrospectively examined the role of hematopoietic cell transplantation (HCT) at first complete remission (CR1) in adults with ALL/LBL after hyper-CVAD. HCT at CR1 resulted in a favorable outcome in ALL/LBL patients after hyper-CVAD frontline therapy.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research

Related Links:

Publication date: October 2020Source: Clinical Lymphoma Myeloma and Leukemia, Volume 20, Issue 10Author(s): Patrick Stelmach, Klaus Wethmar, Christoph Groth, Daniela V. Wenge, Jörn Albring, Jan-Henrik Mikesch, Christoph Schliemann, Christian Reicherts, Wolfgang E. Berdel, Georg Lenz, Matthias Stelljes
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Fenntartó kezelési módok felnőttkori rosszindulatú hematológiai betegségekben. Orv Hetil. 2020 Sep;161(38):1623-1628 Authors: Udvardy M Abstract Maintenance therapy has been the strong and standard element of many acute lymphoblastic leukaemia protocols, used much less frequently and systematically in adult oncohematological disorders. The first adult maintenance efforts appeared in follicular and mantle cell lymphoma (mostly monoclonal antibody based), along with an early maintenance effort to prolong the plateau phase of myeloma. For the time being, after a...
Source: Orvosi Hetilap - Category: General Medicine Authors: Tags: Orv Hetil Source Type: research
era J Abstract The decision to incorporate allogeneic hematopoietic stem cell transplant (allo-HSCT) into front-line therapy in adult acute lymphoblastic leukemia (ALL) should be primarily guided by measurable residual disease (MRD) status and the ALL regimen utilized. While there is no doubt that allo-HSCT benefits patients with poor MRD response after induction or consolidation, the indication of allo-HSCT in cases of good MRD clearance is not clear. As targeted immunotherapies result in high MRD-negative CR rates, early incorporation of these therapies may also prove valuable in reducing the need for HCT in the...
Source: Clinical Lymphoma and Myeloma - Category: Cancer & Oncology Authors: Tags: Clin Lymphoma Myeloma Leuk Source Type: research
Publication date: Available online 16 July 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Satoru Nanno, Kana Matsumoto, Mika Nakamae, Hiroshi Okamura, Mitsutaka Nishimoto, Asao Hirose, Hideo Koh, Yasuhiro Nakashima, Takahiko Nakane, Kunihiko Morita, Masayuki Hino, Hirohisa Nakamae
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 16 July 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Satoru Nanno, Kana Matsumoto, Mika Nakamae, Hiroshi Okamura, Mitsutaka Nishimoto, Asao Hirose, Hideo Koh, Yasuhiro Nakashima, Takahiko Nakane, Kunihiko Morita, Masayuki Hino, Hirohisa Nakamae
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
The effect of post-transplant ponatinib maintenance therapy on outcomes after allogeneic hematopoietic stem cell transplantation in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia has remained unknown. The presented results suggest that survival in the ponatinib group was better than that in the non –ponatinib group and that ponatinib maintenance therapy is safe. The post-transplant ponatinib maintenance strategy might be promising.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
The impact of post-transplant ponatinib maintenance therapy on outcomes after allogeneic hematopoietic stem cell transplantation in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia remains still unknown. This retrospective study suggested that survival in the ponatinib group was better than that in non-ponatinib group and ponatinib maintenance therapy was safety. The post-transplant ponatinib maintenance strategy might be promising.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
Publication date: Available online 27 June 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Sajad Khazal, Partow Kebriaei
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 3 June 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Patrick Stelmach, Klaus Wethmar, Christoph Groth, Daniela V. Wenge, Jörn Albring, Jan-Henrik Mikesch, Christoph Schliemann, Christian Reicherts, Wolfgang E. Berdel, Georg Lenz, Matthias Stelljes
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
In the present report, we have described the clinical course of 34 adult patients who had received blinatumomab or inotuzumab ozogamicin for relapsed or refractory acute lymphoblastic leukemia. Both agents induced high rates of molecular complete remission, with manageable toxicity profiles, allowing 80% of transplantable patients to proceed to allogeneic stem cell transplantation. These data suggest high efficacy and safety for both drugs in a bridge-to-transplantation setting.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
More News: Acute Leukemia | Acute Lymphoblastic Leukemia | Dexamethasone | Hematology | Leukemia | Lymphoma | Methotrexate | Myeloma | Study | Transplants